Maternal Broadly Neutralizing Antibodies Can Select for Neutralization-Resistant, Infant-Transmitted/Founder HIV Variants
David Martínez, Joshua J. Tu, Amit Kumar, Jesse F. Mangold, Riley J. Mangan, Ria Goswami, Elena E. Giorgi, Jui‐Lin Chen, Michael Mengual, Ayooluwa O. Douglas, Holly Heimsath, Kevin O. Saunders, Nathan I. Nicely, Joshua Eudailey, Giovanna E. Hernandez, Papa K. Morgan-Asiedu, Kevin Wiehe, Barton F. Haynes, M. Anthony Moody, Celia C. LaBranche, David C. Montefiori, Feng Gao, Sallie R. Permar
Abstract
Efforts to eliminate MTCT of HIV with antiretroviral therapy (ART) have met little success, with >180,000 infant infections each year worldwide. It is therefore likely that additional immunologic strategies that can synergize with ART will be required to eliminate MTCT of HIV. To this end, understanding the role of maternal HIV Env-specific IgG antibodies in the setting of MTCT is crucial. In this study, we found that maternal-plasma broadly neutralizing antibody (bNAb) responses can select for T/F viruses that initiate infection in infants. We propose that clinical trials testing the efficacy of single bNAb specificities should not include HIV-infected pregnant women, as a single bNAb might select for neutralization-resistant infant-T/F viruses.